Premium
Fecal Microbial Transplantation in Inflammatory Bowel Disease: A Movement Too Big to Be Ignored
Author(s) -
Laffin M,
Madsen KL
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.747
Subject(s) - inflammatory bowel disease , fecal bacteriotherapy , medicine , feces , disease , transplantation , ulcerative colitis , intensive care medicine , clinical trial , immunology , biology , antibiotics , microbiology and biotechnology , clostridium difficile
The development of new therapies for inflammatory bowel disease is plagued by high costs, potential side effects, and variable levels of effectiveness. Fecal microbial transplant in inflammatory bowel diseases can offer an alternative to traditionally developed pharmacologic therapies and has demonstrated the ability to induce disease remission in randomized control trials. However, questions remain about the ultimate role of this therapy in disease management, including long term safety, and the optimal composition of transplanted stool.